[
    [
        {
            "time": "",
            "original_text": "康泰生物：腺病毒载体新冠疫苗已完成临床前研究并提交了临床试验申请",
            "features": {
                "keywords": [
                    "腺病毒载体",
                    "新冠疫苗",
                    "临床前研究",
                    "临床试验申请"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：腺病毒载体新冠疫苗已完成临床前研究并提交了临床试验申请",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：13价肺炎球菌结合疫苗申请的药品注册批件在审批中",
            "features": {
                "keywords": [
                    "13价肺炎球菌结合疫苗",
                    "药品注册",
                    "审批中"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：13价肺炎球菌结合疫苗申请的药品注册批件在审批中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：实控人杜伟民质押139万股及解押400万股",
            "features": {
                "keywords": [
                    "实控人",
                    "杜伟民",
                    "质押",
                    "解押"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：实控人杜伟民质押139万股及解押400万股",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2021年9月投资策略暨中报总结：政策预期基线变化中消化估值",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "政策预期",
                    "估值"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2021年9月投资策略暨中报总结：政策预期基线变化中消化估值",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "天风证券维持康泰生物买入评级：乙肝疫苗恢复生产，新冠疫苗带来业绩弹性",
            "features": {
                "keywords": [
                    "天风证券",
                    "买入评级",
                    "乙肝疫苗",
                    "新冠疫苗",
                    "业绩弹性"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天风证券维持康泰生物买入评级：乙肝疫苗恢复生产，新冠疫苗带来业绩弹性",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]